Bishkek, Kyrgyzstan, August 19, 2017 --(PR.com)-- Registered since 2015, Pharmaceutical Company CJSC ARAY announced today that it is in active research and development phase of a new Hormone Replacement Therapy (HRT) drug, called SUSTADREN (TM), which aims to prolong health and vitality of men over forty. This new revolutionary testosterone mix will allow the user to overcome age barriers and increase life expectancy.

The top quality active pharmaceutical ingredients and oils are going to be used as adjuvants in the product to ensure the best quality and compliance with international standards. Thus, all delivered ingredients and substances will comply with the pharmacopoeia grade requirements, including the British (BP) and European Pharmacopoeia (EP), as well as GMP.

The Company is looking to develop and produce a number of oral and injectable drugs of hormonal origin as housed by own GMP pharmaceutical plant in Bishkek, Kyrgyz Republic in the nearest future.